BASAGLAR pharmacodynamic (PD) profile
BASAGLAR and Lantus (US-approved) PD properties over a 24-hour period6
A phase 1 randomized, double-blind, single-dose, 2-treatment, 4-period, crossover, replicate treatment, euglycemic clamp study with 91 healthy subjects evaluated the PK and PD profiles for BASAGLAR and Lantus (US-approved) given subcutaneously as single, 0.5 unit/kg doses.6
PD results: Based on statistical comparisons of total glucose infusion over the clamp duration (Gtot) and maximum glucose infusion rate (Rmax) of BASAGLAR and Lantus (US-approved), the ratios of LS geometric means were 0.91 and 0.93, respectively, for Gtot and Rmax, with 90% CIs for the ratios contained within the prespecified interval of 0.80 to 1.25.6
The PD profile of BASAGLAR demonstrated sustained glucose-lowering activity over 24 hours with no pronounced peak1,6
SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Accidental mix-ups between another insulin glargine product (100 units/mL) and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.